Content |
2024: Expansion of the plant for 300 million rubles
The largest Russian manufacturer of vacuum systems for taking blood, Granat Bio Tech, has implemented a project worth 300 million rubles to expand production capacities. Most of these investments (168 million rubles) came from a preferential loan received from the Industrial Development Fund (FRP). This was reported by the press service of the special economic zone (SEZ) "Dubna," the resident of which is the company.
"Garnet Bio Tech" launched in the SEZ the second and third lines for the manufacture of vacuum tubes under the Acti-Fine brand for the collection, storage and transportation of venous blood. The capacity of the new production is up to 80 million units per year, thus the total annual production volume increased to 180 million units.
It is noted that the technological lines are designed in such a way that they allow you to produce a wide range of products - more than 800 nomenclature units, including with rare and specific reagents, quickly introduce new types of products into production.
According to the company, by February 2024, the share of imports of vacuum tubes to Russia is about 69%. With the launch of new lines, Granat Bio Tech plans to increase its market share from 14% to 20%, thereby squeezing out imports.
The company invested over 2.7 billion rubles in the project implemented on the territory of the special economic zone by the beginning of February 2024. The company has created 134 jobs. Medical products of the resident are delivered to the largest laboratories in Russia.
According to the Granat Bio Tech company, its specialists carry out strict quality control of each stage of production. Thus, the production received international certificates, and a conclusion was obtained confirming the production of industrial products on the territory of the Russian Federation.[1]
2021: The launch of the production of needles for the collection of venous blood in the SEZ "Dubna"
In mid-February 2021, it became known about the launch by Garnet Bio Tech of serial production of bilateral needles with an imaging camera for taking venous blood. The project should significantly reduce the share of imported products in this area.
"Garnet Bio Tech" has placed its enterprise on the special economic zone (SEZ) "Dubna." There is a production of plastic components of the needle (imaging cameras and caps), as well as assembly production of the needle, including labeling and packaging.
The visualization camera on the needle will allow the medical staff to determine the moment of the needle entering the patient's vein as correctly as possible, reducing possible painful sensations, hematoma formation and injuries.
About 80 million double-sided needles with an imaging camera are scheduled to be produced annually at this plant. The products will be sold through a network of distributors, as well as delivered directly to medical institutions.
Garnet Bio Tech became the first Russian full-cycle enterprise with specialized products, the company expects to reduce the share of imports in the domestic market from 100% to 70%. Previously, most of the products for the needs of laboratories and clinics of the Russian Federation were imported from the countries of Southeast Asia, the USA and the European Union.
The total project budget is 487 million rubles. Of these, 389.3 million is a preferential loan under the Component Products program, which was provided to the company by the Industrial Development Fund (FRP) for the purchase of modern equipment in June 2019, the FRP press service said.
According to the SPARK-Interfax system, by February 2021, the 100% owner of Granat Bio Tech is Granat Invest LLC, which is owned by Invitro founder Alexander Ostrovsky (20.70%), its structure is OMB LLC (23.4%), Elena Kulikovskaya (23.4%), Pavel Kulikovsky (9%) and Alexander Shishov (11.5%).[2]
2019
A center for sterilization of medical devices will be opened in the Moscow region
At the end of November 2019, the Accent management company, the manufacturer of medical devices Granat Bio Tech, the Medical and Technical Cluster of the Moscow Region and Dubna the leadership of the Special Economic Zone (SEZ) signed an agreement on the creation of the Center for Electron Beam Processing of Medical Devices. here More.
Production of Acti-Fine venous blood vacuum tubes
On November 7, 2019, it became known that the Granat Bio Tech plant began production of disposable medical devices.
So far, production has been reported to focus on Acti-Fine venous blood vacuum tubes. The plant's capacity is able to close exactly a quarter of the total demand of the Russian market for these products. However, Garnet Bio Tech is focused on entering the international arena.
 | Modern laboratory diagnostics require high technologies, the highest quality equipment and consumables, we at Invitro understand this as no one. That is why our partner participation in the creation of the production of modern disposable medical devices, in which the company "Garnet Bio Tech" specializes, is a completely logical and natural step. We are confident that Russian companies in November 2019 have quite reached the level of technological perfection in order to compete on equal terms with the best foreign manufacturers. Moreover, modern equipment was used at the Granat Bio Tech plant in Dubna. told Alexander Ostrovsky, founder and general director of Invitro |  |
According to the company, as of November 2019, the main feature of Garnet Bio Tech is the full cycle of production of vacuum tubes for taking venous blood Acti-Fine.
As of November 2019, Garnet Bio Tech is an environmentally friendly enterprise with production capacities of over 6,000 sq.m. The plant was assigned the energy efficiency class "Highest A +."
Specialists "Garnet Bio Tech" together with European colleagues have developed a unique assembly automated complex. In fact, this is a robot that can quickly switch from production of one product range to another.
As of November 2019, special attention is paid to production standards. For example, more than 500 quality sensors are installed during the test tube assembly step. In total, each tube is tested for 45 different parameters.
The quality of the first line of products has already attracted the attention of potential customers. Garnet Bio Tech has concluded a number of contracts with Russian companies.
In the first year of operation, the Russian manufacturer intends to produce 100 million vacuum tubes. This is a quarter of the total need for the domestic market. According to the plan, in 2021, Garnet Bio Tech will double its production capacity. In addition, the range of products will be expanded: mass production of medical bilateral needles for taking venous blood will begin.
2017: Construction of an enterprise for the production of medical products
In April 2017, a resident of the Dubna Special Economic Zone (SEZ) - the Granat Bio Tech company - laid the foundation stone for a new enterprise for the production of disposable medical products for domestic clinical and diagnostic laboratories.
In this research and production complex (NPK), first (by the end of 2018) medical containers will be made, and then (in 2019) - test tubes, needles and holders. The plant will also develop technologies for the production of medical devices.
The Minister of Investments and Innovations of the Moscow Region Denis Butsaev, who took part in the ceremony of starting the construction of the enterprise, said that the products produced there will compete with foreign solutions, since it will be much cheaper.
| | This resident joined us in 2016, has already prepared the territory and entered the construction site. By the end of next year, the company plans to launch the first stage - an enterprise for the production of special competitive containers for medical purposes, - said Denis Butsaev. | |
Alexander Shishov, General Director of Granat Bio Tech, said that the total area of three buildings of the future research and production complex will be 17 thousand. square meters. When the enterprise reaches full capacity, the products manufactured by Granat Bio Tech will occupy up to 30% of the Russian market for vacuum tubes for taking venous blood, he said.
According to him, in parallel with the construction of the walls of the future enterprise, equipment is being manufactured and legal issues are being resolved - all this will take about a year. Work on the construction of the NPK is being carried out ahead of schedule, Shishov assured.
The project attracted investments in the amount of 1.25 billion rubles. The planned headcount of the future plant is 152 people.[3]
2016: Creation of "Grenade Bio Tech"
The medical research and production complex "Garnet Bio Tech" was created in 2016 at the expense of private investors. The volume of financial investments at the first stage exceeded 2.1 billion rubles. The main partner is the largest Russian holding Invitro, specializing in laboratory diagnostics and the provision of medical services.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |